Single arms prospective phase II study of SBRT for oligometastatases from colorectal cancer, the primary concerns are treatment efficacy and toxicities.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18-75 years
Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1
Diagnosis by pathological examination
Primary lesion is under control by surgery
Adequate blood counts:
* White blood cell count ≥3.5 x 109/L
* Haemoglobin levels ≥100g/L
* Platelet count ≥100 x 109/L
* Creatinine levels ≤1.0× upper normal limit (UNL)
* Urea nitrogen levels ≤1.0× upper normal limit (UNL)
* Alanine aminotransferase (ALT) ≤1.5× upper normal limit (UNL)
* Aspartate aminotransferase (AST) ≤1.5× upper normal limit (UNL)
* Alkaline phosphatase (ALP) ≤1.5× upper normal limit (UNL)
* Total bilirubin (TBIL) ≤1.5× upper normal limit (UNL)
You may not be if
Primary lesion is not under control
Pancreatic carcinoma
Oligometastases could not be located
Pregnancy or breast feeding
Symptoms or history of peripheral neuropathy
Clareo Health | Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer
